Replimune Group (NASDAQ:REPL) Rating Increased to Overweight at JPMorgan Chase & Co.

Replimune Group (NASDAQ:REPL) was upgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a note issued to investors on Friday, Marketbeat reports.

Several other analysts have also recently commented on REPL. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Wedbush upped their target price on shares of Replimune Group from $2.00 to $6.00 and gave the company a “neutral” rating in a research report on Monday, June 1st. Weiss Ratings upgraded shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $4.88.

Replimune Group Stock Up 0.7%

Replimune Group stock traded up $0.08 during mid-day trading on Friday, hitting $11.21. The company had a trading volume of 3,671,419 shares, compared to its average volume of 4,650,596. The stock’s 50 day moving average price is $6.05 and its two-hundred day moving average price is $7.27. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $925.73 million, a PE ratio of -3.21 and a beta of 0.91. Replimune Group has a 12 month low of $1.50 and a 12 month high of $13.24.

Insider Activity at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Hedge funds have recently made changes to their positions in the company. Fcpm Iii Services B.V. grew its stake in Replimune Group by 6.4% during the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after purchasing an additional 248,672 shares during the last quarter. Erste Asset Management GmbH boosted its position in Replimune Group by 13,597.5% in the third quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock valued at $7,074,000 after buying an additional 1,618,100 shares during the last quarter. Braidwell LP increased its holdings in Replimune Group by 550.3% in the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after buying an additional 2,327,205 shares during the period. Quinn Opportunity Partners LLC purchased a new position in Replimune Group during the 3rd quarter worth approximately $2,727,000. Finally, Jefferies Financial Group Inc. acquired a new stake in Replimune Group during the 4th quarter valued at approximately $6,942,000. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.